GlassScriptPhysician profile
Smita K Rumalla
NPI 1932260668
$2,244.72
in general payments reported to CMS, 2019-2025
34 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $46.93 · 2021: $295 · 2022: $293 · 2023: $366 · 2024: $834 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $693.09 | 2021-2024 | Qelbree |
| Glaxosmithkline, LLC. | $366.50 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.25 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $78.30 | 2021-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $65.20 | 2019-2020 | |
| Cranial Technologies, INC | $62.89 | 2021-2024 | Doc Band |
| Pfizer INC. | $56.38 | 2023-2025 | |
| Sanofi Pasteur INC. | $54.81 | 2021-2025 | |
| Abbvie INC. | $49.78 | 2021-2024 | Ubrelvy |
| Merck Sharp & Dohme LLC | $49.10 | 2022-2024 | Capvaxive, Vaxelis, Gardasil 9 |
| Lilly USA, LLC | $48.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $41.71 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.73 | 2023-2024 | Flumist Quadrivalent, Airsupra |
| Ethicon US, LLC | $34.94 | 2019-2022 | |
| Dynavax Technologies Corporation | $32.75 | 2022-2024 | Heplisav-B |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $31.59 | 2023 | Venaseal |
| Seqirus USA INC | $30.08 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Corium, LLC | $29.03 | 2025 | Azstarys |
| Genentech USA, INC. | $28.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.16 | 2023 | |
| Amgen INC. | $26.87 | 2019 | |
| Ironshore Pharmaceuticals INC. | $22.67 | 2023 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $22.40 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2023 | Vpriv |
| Eisai INC. | $18.71 | 2021 | |
| Amarin Pharma, INC. | $17.73 | 2019 | |
| Antares Pharma, INC. | $15.99 | 2021 | |
| Kaleo, INC. | $15.73 | 2022 | |
| Dexcom, INC. | $15.64 | 2022 | |
| Exact Sciences Corporation | $14.94 | 2024 | |
| Inspire Medical Systems, INC. | $13.95 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $13.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Rumalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.